Eli Lilly and Company (NYSE:LLY) is one of the best performing pharma stocks in 2025. Eli Lilly and Company (NYSE:LLY) ...

For much of the past decade, trillion-dollar market capitalizations have been dominated by tech driven by platform economics, ...

Eli Lilly and Company (NYSE:LLY) is one of the Best Unstoppable Growth Stocks to Buy Right Now. On January 7, Michael Yee ...

Both companies are benefiting from the obesity drug theme, but one stock looks much more attractive than the other.

Eli Lilly LLY has pursued a series of acquisitions since early 2025 to strengthen its pipeline and support long-term growth amid intensifying competition in the obesity space. While cardiometabolic ...

ClearBridge Investments, an investment management company, released its “ClearBridge Large Cap Growth Strategy” ...

Eli Lilly shares surged over 4.5% on analyst upgrades, acquisition rumors involving Ventyx Biosciences, and a new $1.3 ...

Ventyx shares jumped in after-hours trading following reports that Eli Lilly is in advanced talks to acquire the biopharma ...

Eli Lilly and Company rated Buy: incretin/obesity growth, ZEPBOUND & orforglipron access strategy, pipeline deals, ...

Eli Lilly stays a Strong Buy as GLP-1 demand drives revenue/EPS beats, margin gains, and pipeline upside. Click here to read ...

The stock of Eli Lilly (LLY) is down 4% on news that rival Novo Nordisk (NVO) has begun selling its highly anticipated weight ...